Targets › VZVE
1 program from 1 company in 1 trial: 1 Phase 4; Immunology; next expected readout Jun 2032.
Open in Phaseline: the race on VZVE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Sao Paulo General Hospital | Recombinant Herpes Zoster Vaccine (RZV/Shingrix®) Recombinant VZV glycoprotein E with AS01B adjuvant system | VZVE | Phase 4 | Rheumatoid Arthritis | Jun 2032 |
Rheumatoid Arthritis (1)
other (1)
University of Sao Paulo General Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.